IG
ARIA

ING Group’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

ING Group’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-55,000
Closed -$754K – 645
2016
Q3 		$754K Buy
+55,000
New +$552K 0.01% 324
2016
Q1 		– Sell
-99,935
Closed -$624K – 738
2015
Q4 		$624K Buy
99,935
+42,295
+73% +$278K ﹤0.01% 549
2015
Q3 		$337K Buy
+57,640
New +$444K ﹤0.01% 528
2015
Q1 		– Sell
-309,652
Closed -$2.13M – 854
2014
Q4 		$2.13M Buy
+309,652
New +$1.94M 0.01% 482
2014
Q3 		– Sell
-245,699
Closed -$1.56M – 693
2014
Q2 		$1.56M Buy
245,699
+11,750
+5% +$80.8K 0.01% 485
2014
Q1 		$1.89M Buy
+233,949
New +$1.82M 0.01% 497
2013
Q4 		– Sell
-376,668
Closed -$6.93M – 821
2013
Q3 		$6.93M Buy
+376,668
New +$7.31M 0.03% 343

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

ING Group's ARIA Position: Q4 2016 in Review

ING Group sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 55,000 shares — an estimated $754K sold.

ING Group first reported a position in ARIA in Q3 2013 and held it in 7 quarters. The position peaked at $6.93M in Q3 2013. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • ING Group reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • ING Group sold 55,000 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $754K.
  • ING Group first reported a position in Ariad Pharmaceuticals Inc in Q3 2013 and held it in 7 quarters.
  • ING Group's Ariad Pharmaceuticals Inc position peaked at $6.93M in Q3 2013.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on ING Group's 13F filing for Q4 2016, filed 6 Feb 2017.